Market Challenges And Opportunities

Artificial Insemination Market Dynamics

Major pharmaceutical companies are vigorously developing products that are in clinical and preclinical trials and launching new insemination kits that have demonstrated potential benefits, which in turn is propelling the artificial insemination market growth. For instance, 2015 clinical trial study of Stork OTC kit showed effectiveness at delivering higher concentration of sperm to the cervix than natural intercourse. The Stork OTC delivered 3.23x higher value of sperm concentration to around 85% of the subjects in the study, whereas the remaining 15% showed no change in sperm concentration at the cervix. The Stork OTC received FDA over-the-counter approval in July 2014. The kit helps collect, insert, and transport sperms directly at the opening of the cervix for prolong duration, providing sperms the opportunity to enter into the uterus. The Stork OTC provides a safe and simple way for users to avoid unfavorable vaginal environment, to deliver the sperm.

Moreover, according to the National Women’s Health Resource Center, infertility impacts over 20 million women. According to 2017 United Nations World Population prospects report, total fertility is expected to decrease from 2.43 to 2.39 (children per woman) between 2020 and 2030. Increasing incidence of infertility among the global populace is majorly boosting growth of the artificial insemination market.

However, stringent regulations being implemented by most countries regarding who is applicable to receive fertility treatments, is hindering growth of the artificial insemination market size. For instance, Italy and France forbid lesbian couples and single women from using artificial insemination. Italy and Austria are among those banning all sperm and egg donations for IVF. Norway and Germany ban egg donations, however, allow sperm donations.